FUTURE RESEARCH GAPS IN ECHINACEA PURPUREA THERAPEUTICS
DOI:
https://doi.org/10.69980/z3c30877Keywords:
Herbal Medicine, Standardization, Phytochemical Variability, Pharmacokinetics, Clinical TranslationAbstract
Herbal medicine research faces various hurdles that hinder its inclusion into current healthcare system. A major concern is the non-uniformity and non-uniformity of the phytochemical constituents, affecting therapeutic uniformity and reproducibility. Further limiting scientific confirmation is a not sufficient understanding of mechanisms of action. Moreover, comprehensive studies of complex and complicated herbal compositions are constrained by the limited application of state-of-the-art omics technologies. Clinical trials are often limited to therapeutic indications and poorly designed, whereas preclinical studies often have discrepancies. Poor pharmacokinetic and bioavailability data compound the process of dosage optimization. The toxicological profile, the interactions between drugs and herbs, and long-term safety issues have not yet been sufficiently investigated. Adulteration, quality control, formulation and administration of the drug are other factors contributing to market variability. Regulatory hurdles add to the delay in clinical translation, as do real-world data limitations. To overcome these limitations and promote the development and wide-spread use of herbal remedies, standardized procedures, cutting-edge technologies, and comprehensive clinical evaluation are required.
References
1.Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005 Aug;57(8):929-54. doi: 10.1211/0022357056127. PMID: 16102249.
2.Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003 Jan;10(1):66-86. doi: 10.1078/094471103321648692. PMID: 12622467.
3.Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med. 2007 Jun;73(7):615-23. doi: 10.1055/s-2007-981531. Epub 2007 May 31. PMID: 17538868.
4.Burlou-Nagy C, Bănică F, Jurca T, Vicaș LG, Marian E, Muresan ME, Bácskay I, Kiss R, Fehér P, Pallag A. Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review. Plants (Basel). 2022 May 5;11(9):1244. doi: 10.3390/plants11091244. PMID: 35567246; PMCID: PMC9102300.
5.Manayi A, Vazirian M, Saeidnia S. Echinacea purpurea: Pharmacology, phytochemistry and analysis methods. Pharmacogn Rev. 2015 Jan-Jun;9(17):63-72. doi: 10.4103/0973-7847.156353. PMID: 26009695; PMCID: PMC4441164.
6.Percival SS. Use of echinacea in medicine. Biochem Pharmacol. 2000 Jul 15;60(2):155-8. doi: 10.1016/s0006-2952(99)00413-x. PMID: 10825459.
7.Senchina DS, Wu L, Flinn GN, Konopka del N, McCoy JA, Widrlechner MP, Wurtele ES, Kohut ML. Year-and-a-half old, dried Echinacea roots retain cytokine-modulating capabilities in an in vitro human older adult model of influenza vaccination. Planta Med. 2006 Oct;72(13):1207-15. doi: 10.1055/s-2006-947254. Epub 2006 Oct 4. Erratum in: Planta Med. 2006 Dec;72(15):1440. Widrelechner, Mark P [corrected to Widrlechner, Mark P]. PMID: 17021999; PMCID: PMC1976405.
8.Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis. 2007 Jul;7(7):473-80. doi: 10.1016/S1473-3099(07)70160-3. Erratum in: Lancet Infect Dis. 2007 Sep;7(9):580. PMID: 17597571; PMCID: PMC7106401.
9.Ahmadi F. Phytochemistry, Mechanisms, and Preclinical Studies of Echinacea Extracts in Modulating Immune Responses to Bacterial and Viral Infections: A Comprehensive Review. Antibiotics (Basel). 2024 Oct 9;13(10):947. doi: 10.3390/antibiotics13100947. PMID: 39452214; PMCID: PMC11504277.
10.Huntley AL, Thompson Coon J, Ernst E. The safety of herbal medicinal products derived from Echinacea species: a systematic review. Drug Saf. 2005;28(5):387-400. doi: 10.2165/00002018-200528050-00003. PMID: 15853441.
11.Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8. PMID: 30231877; PMCID: PMC6145203.
12.Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol. 2010 Mar 1;243(2):198-216. doi: 10.1016/j.taap.2009.12.005. Epub 2009 Dec 16. PMID: 20018204.
13.Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005 Aug;57(8):929-54. doi: 10.1211/0022357056127. PMID: 16102249.
14.Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003 Jan;10(1):66-86. doi: 10.1078/094471103321648692. PMID: 12622467.
15.Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med. 2007 Jun;73(7):615-23. doi: 10.1055/s-2007-981531. Epub 2007 May 31. PMID: 17538868.
16.Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003 Jan;10(1):66-86. doi: 10.1078/094471103321648692. PMID: 12622467.
17.Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013 Oct 11;11:222. doi: 10.1186/1741-7015-11-222. Retraction in: BMC Med. 2024 Jul 4;22(1):279. doi: 10.1186/s12916-024-03504-x. PMID: 24120035; PMCID: PMC3851815.
18.Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, Schoop R, Gertsch J. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol. 2009;9(7–8):850–858. PMID: 19376261 (PubMed)
19.Perry NB, Burgess EJ, Glennie VL. Echinacea standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem. 2001 Apr;49(4):1702-6. doi: 10.1021/jf001331y. PMID: 11308313.
20.Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH, Gertsch J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem. 2006 May 19;281(20):14192-206. doi: 10.1074/jbc.M601074200. Epub 2006 Mar 17. PMID: 16547349.
21.Manayi A, Vazirian M, Saeidnia S. Echinacea purpurea: Pharmacology, phytochemistry and analysis methods. Pharmacogn Rev. 2015 Jan-Jun;9(17):63-72. doi: 10.4103/0973-7847.156353. PMID: 26009695; PMCID: PMC4441164.
22.Barrett B, Brown R, Rakel D, Mundt M, Bone K, Barlow S, Ewers T. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010 Dec 21;153(12):769-77. doi: 10.7326/0003-4819-153-12-201012210-00003. PMID: 21173411; PMCID: PMC3056276.
23.Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, Pezzuto JM, Viljoen A. Best practice in research - Overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020 Jan 10; 246:112230. doi: 10.1016/j.jep.2019.112230. Epub 2019 Sep 14. PMID: 31526860.
24.Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt. Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005 Aug;57(8):929-54. doi: 10.1211/0022357056127. PMID: 16102249.
25.Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003 Jan;10(1):66-86. doi: 10.1078/094471103321648692. PMID: 12622467.
26.Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med. 2007 Jun;73(7):615-23. doi: 10.1055/s-2007-981531. Epub 2007 May 31. PMID: 17538868.
27.Pellati F, Benvenuti S, Melegari M, Lasseigne T. Variability in the composition of anti-oxidant compounds in Echinacea species by HPLC. Phytochem Anal. 2005 Mar-Apr;16(2):77-85. doi: 10.1002/pca.815. PMID: 15881113.
28.Thomsen MO, Fretté XC, Christensen KB, Christensen LP, Grevsen K. Seasonal variations in the concentrations of lipophilic compounds and phenolic acids in the roots of Echinacea purpurea and Echinacea pallida. J Agric Food Chem. 2012 Dec 12;60(49):12131-41. doi: 10.1021/jf303292t. Epub 2012 Dec 3. PMID: 23181941.
29.Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005 Aug;57(8):929-54. doi: 10.1211/0022357056127. PMID: 16102249.
30.Manayi A, Vazirian M, Saeidnia S. Echinacea purpurea: Pharmacology, phytochemistry and analysis methods. Pharmacogn Rev. 2015 Jan-Jun;9(17):63-72. doi: 10.4103/0973-7847.156353. PMID: 26009695; PMCID: PMC4441164.
31.Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-α gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 2004;577(3):563–569. PMID: 15556644 (PubMed)
32.Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013 Oct 11; 11:222. doi: 10.1186/1741-7015-11-222. Retraction in: BMC Med. 2024 Jul 4;22(1):279. doi: 10.1186/s12916-024-03504-x. PMID: 24120035; PMCID: PMC3851815.
33.Speroni E, Govoni P, Guizzardi S, Renzulli C, Guerra MC. Anti-inflammatory and cicatrizing activity of Echinacea pallida Nutt. root extract. J Ethnopharmacol. 2002 Feb;79(2):265-72. doi: 10.1016/s0378-8741(01)00391-9. PMID: 11801391.
34.Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005 Aug;57(8):929-54. doi: 10.1211/0022357056127. PMID: 16102249.
35.Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003 Jan;10(1):66-86. doi: 10.1078/094471103321648692. PMID: 12622467.
36.Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z. Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J Leukoc Biol. 2000 Oct;68(4):503-10. PMID: 11037971.
37.Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med. 2007 Jun;73(7):615-23. doi: 10.1055/s-2007-981531. Epub 2007 May 31. PMID: 17538868.
38.Spelman K, Burns J, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern Med Rev. 2006 Jun;11(2):128-50. PMID: 16813462.
39.Stevenson LM, Matthias A, Banbury L, Penman KG, Bone KM, Leach DL, Lehmann RP. Modulation of macrophage immune responses by Echinacea. Molecules. 2005 Oct 31;10(10):1279-85. doi: 10.3390/10101279. PMID: 18007520; PMCID: PMC6147727.
40.Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997 Jul;19(7):371-9. doi: 10.1016/s0192-0561(97)00061-1. PMID: 9568541.
41.Luettig B, Steinmüller C, Gifford GE, Wagner H, Lohmann-Matthes ML. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. J Natl Cancer Inst. 1989 May 3;81(9):669-75. doi: 10.1093/jnci/81.9.669. PMID: 2785214.
42.Zhai Z, Haney D, Wu L, Solco A, Murphy PA, Wurtele ES, Kohut ML, Cunnick JE. Alcohol extracts of Echinacea inhibit production of nitric oxide and tumor necrosis factor-alpha by macrophages in vitro. Food Agric Immunol. 2007 Sep;18(3-4):221-236. doi: 10.1080/09540100701797363. PMID: 18458735; PMCID: PMC2366993.
43.Vieira SF, Gonçalves VMF, Llaguno CP, Macías F, Tiritan ME, Reis RL, Ferreira H, Neves NM. On the Bioactivity of Echinacea purpurea Extracts to Modulate the Production of Inflammatory Mediators. Int J Mol Sci. 2022 Nov 6;23(21):13616. doi: 10.3390/ijms232113616. PMID: 36362404; PMCID: PMC9659013.
44.Catanzaro M, Corsini E, Rosini M, Racchi M, Lanni C. Immunomodulators Inspired by Nature: A Review on Curcumin and Echinacea. Molecules. 2018 Oct 26;23(11):2778. doi: 10.3390/molecules23112778. PMID: 30373170; PMCID: PMC6278270.
45.Hudson JB. Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases. J Biomed Biotechnol. 2012; 2012:769896. doi: 10.1155/2012/769896. Epub 2011 Oct 26. PMID: 22131823; PMCID: PMC3205674.
46.Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, Schoop R, Gertsch J. Synergistic immunopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol. 2009 Jul;9(7-8):850-8. doi: 10.1016/j.intimp.2009.03.006. Epub 2009 Mar 19. PMID: 19303464.
47.Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 2004 Nov 19;577(3):563-9. doi: 10.1016/j.febslet.2004.10.064. PMID: 15556647.
48.Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005 May;5(5):400-11. doi: 10.1038/nri1602. PMID: 15864274.
49.Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, Schoop R, Gertsch J. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol. 2009 Jul;9(7-8):850-8. doi: 10.1016/j.intimp.2009.03.006. Epub 2009 Mar 19. PMID: 19303464.
50.Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med. 2007 Jun;73(7):615-23. doi: 10.1055/s-2007-981531. Epub 2007 May 31. PMID: 17538868.
51.Sharma M, Schoop R, Hudson JB. Echinacea as an antiinflammatory agent: the influence of physiologically relevant parameters. Phytother Res. 2009 Jun;23(6):863-7. doi: 10.1002/ptr.2714. PMID: 19107735.
52.Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 2004 Nov 19;577(3):563-9. doi: 10.1016/j.febslet.2004.10.064. PMID: 15556647.
53.Dalby-Brown L, Barsett H, Landbo AK, Meyer AS, Mølgaard P. Synergistic antioxidative effects of alkamides, caffeic acid derivatives, and polysaccharide fractions from Echinacea purpurea on in vitro oxidation of human low-density lipoproteins. J Agric Food Chem. 2005 Nov 30;53(24):9413-23. doi: 10.1021/jf0502395. PMID: 16302756.
54.Lin J, Yang Q, Su J, Xing H, Pan H, Yu JB, Bai M, Li Y, Huang HY, Liang X, Wu H. Transcriptomics and metabolomics analyses of the effects of plant age and organ on caffeic acid derivative accumulation in Echinacea purpurea. Plant Physiol Biochem. 2025 Sep; 226:110051. doi: 10.1016/j.plaphy.2025.110051. Epub 2025 May 19. PMID: 40413959.
55.Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Res. 2009 Aug;83(2):165-70. doi: 10.1016/j.antiviral.2009.04.009. Epub 2009 May 3. PMID: 19409931.
56.Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009 Jan;10(1):57-63. doi: 10.1038/nrg2484. PMID: 19015660; PMCID: PMC2949280.
57.Matthias A, Banbury L, Stevenson LM, Bone KM, Leach DN, Lehmann RP. Alkylamides from echinacea modulate induced immune responses in macrophages. Immunol Invest. 2007;36(2):117-30. doi: 10.1080/08820130600745786. PMID: 17365014.
58.Perry NB, Burgess EJ, Glennie VL. Echinacea standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem. 2001 Apr;49(4):1702-6. doi: 10.1021/jf001331y. PMID: 11308313.
59.Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016 Sep 15;537(7620):347-55. doi: 10.1038/nature19949. PMID: 27629641.
60.Matthias A, Banbury L, Bone KM, Leach DN, Lehmann RP. Echinacea alkylamides modulate induced immune responses in T-cells. Fitoterapia. 2008 Jan;79(1):53-8. doi: 10.1016/j.fitote.2007.07.012. Epub 2007 Aug 11. PMID: 17855021.
61.Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med. 2007 Jun;73(7):615-23. doi: 10.1055/s-2007-981531. Epub 2007 May 31. PMID: 17538868.
62.Kim HK, Verpoorte R. Sample preparation for plant metabolomics. Phytochem Anal. 2010 Jan-Feb;21(1):4-13. doi: 10.1002/pca.1188. PMID: 19904733.
63.Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9. doi: 10.1038/nrm3314. PMID: 22436749; PMCID: PMC3682684.
64.Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature. 2008 Oct 23;455(7216):1054-6. doi: 10.1038/4551054a. PMID: 18948945.
65.Fiehn O. Metabolomics--the link between genotypes and phenotypes. Plant Mol Biol. 2002 Jan;48(1-2):155-71. PMID: 11860207.
66.Wolfender JL, Rudaz S, Choi YH, Kim HK. Plant metabolomics: from holistic data to relevant biomarkers. Curr Med Chem. 2013;20(8):1056-90. PMID: 23210790.
67.Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022 Feb;43(2):136-150. doi: 10.1016/j.tips.2021.11.004. Epub 2021 Dec 9. PMID: 34895945.
68.Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008 Nov;4(11):682-90. doi: 10.1038/nchembio.118. PMID: 18936753.
69.Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013 Mar;11(2):110-20. doi: 10.1016/S1875-5364(13)60037-0. PMID: 23787177.
70.Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011 Mar;8(3):184-7. doi: 10.1038/nrclinonc.2010.227. PMID: 21364692.
71.Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 2015 Dec;33(8):1582-1614. doi: 10.1016/j.biotechadv.2015.08.001. Epub 2015 Aug 15. PMID: 26281720; PMCID: PMC4748402.
72.Yang L, Yang Y, Huang L, Cui X, Liu Y. From single- to multi-omics: future research trends in medicinal plants. Brief Bioinform. 2023 Jan 19;24(1):bbac485. doi: 10.1093/bib/bbac485. PMID: 36416120; PMCID: PMC9851310.
73.Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995 Mar;12(3):413-20. doi: 10.1023/a:1016212804288. PMID: 7617530.
74.Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002 Jul;19(7):921-5. doi: 10.1023/a:1016473601633. PMID: 12180542.
75.Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003 Mar;2(3):192-204. doi: 10.1038/nrd1032. PMID: 12612645.
76.Hartung T. Perspectives on In Vitro to In Vivo Extrapolations. Appl In Vitro Toxicol. 2018 Dec 1;4(4):305-316. doi: 10.1089/aivt.2016.0026. Epub 2018 Dec 8. PMID: 31890748; PMCID: PMC6309130.
77.Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a. PMID: 22460880.
78.Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos. 1998 Dec;26(12):1202-12. PMID: 9860929.
79.Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014 Jan;32(1):40-51. doi: 10.1038/nbt.2786. PMID: 24406927.
80.van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR. Can animal models of disease reliably inform human studies? PLoS Med. 2010 Mar 30;7(3):e1000245. doi: 10.1371/journal.pmed.1000245. PMID: 20361020; PMCID: PMC2846855.
81.Ioannidis JP. Extrapolating from animals to humans. Sci Transl Med. 2012 Sep 12;4(151):151ps15. doi: 10.1126/scitranslmed.3004631. PMID: 22972841.
82.Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011 Aug 31;10(9):712. doi: 10.1038/nrd3439-c1. PMID: 21892149.
83.Langhans SA. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front Pharmacol. 2018 Jan 23;9:6. doi: 10.3389/fphar.2018.00006. PMID: 29410625; PMCID: PMC5787088.
84.Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470. PMID: 15286737.
85.Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020 Jul 14;18(7):e3000410. doi: 10.1371/journal.pbio.3000410. PMID: 32663219; PMCID: PMC7360023.
86.Zhu AZ. Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. Future Sci OA. 2018 Apr 23;4(5):FSO306. doi: 10.4155/fsoa-2017-0152. PMID: 29796306; PMCID: PMC5961452.
87.Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S73-80. doi: 10.1016/s0928-0987(00)00181-0. PMID: 11033429.
88.Hung HM, Wang SJ, O'Neill RT. Methodological issues with adaptation of clinical trial design. Pharm Stat. 2006 Apr-Jun;5(2):99-107. doi: 10.1002/pst.219. PMID: 17080766.
89.Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995 Mar;12(3):413-20. doi: 10.1023/a:1016212804288. PMID: 7617530.
90.Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007 Mar 21;297(11):1233-40. doi: 10.1001/jama.297.11.1233. PMID: 17374817.
91.Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5. doi: 10.1016/0006-291x(91)91647-u. PMID: 1673839.
92.Hartung T. Food for thought... on animal tests. ALTEX. 2008;25(1):3-16. English, German. doi: 10.14573/altex.2008.1.3. PMID: 18360722.
93.Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010 Jun 25;328(5986):1662-8. doi: 10.1126/science.1188302. PMID: 20576885; PMCID: PMC8335790.
94.Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, Meyer M, Niederalt C, Sevestre M, Siegmund HU, Solodenko J, Thelen K, Telle U, Weiss W, Wendl T, Willmann S, Lippert J. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011 Feb 24;2:4. doi: 10.3389/fphys.2011.00004. PMID: 21483730; PMCID: PMC3070480.
95.Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23. PMID: 23974980; PMCID: PMC3753504.
96.Sun H, Chow EC, Liu S, Du Y, Pang KS. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):395-411. doi: 10.1517/17425255.4.4.395. PMID: 18433344.
97.McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol. 2014 Jan 1;87(1):162-71. doi: 10.1016/j.bcp.2013.08.006. Epub 2013 Aug 14. PMID: 23954708.
98.Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470. PMID: 15286737.
99.Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008 Sep;19(5):640-8. doi: 10.1097/EDE.0b013e31818131e7. Erratum in: Epidemiology. 2009 Jul;20(4):629. PMID: 18633328.
100.Strom BL. How the US drug safety system should be changed. JAMA. 2006 May 3;295(17):2072-5. doi: 10.1001/jama.295.17.2072. PMID: 16670415.
101.Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006 Jan;5(1):27-36. doi: 10.1038/nrd1927. PMID: 16485344.
102.Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12. doi: 10.1073/pnas.1222878110. Epub 2013 Feb 11. PMID: 23401516; PMCID: PMC3587220.
103.Langhans SA. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front Pharmacol. 2018 Jan 23;9:6. doi: 10.3389/fphar.2018.00006. PMID: 29410625; PMCID: PMC5787088.
104.Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062. PMID: 28679092.
105.Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014 Sep;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. Epub 2014 Jul 15. PMID: 25185190; PMCID: PMC4167608.
106.Hall C 3rd. Echinacea as a functional food ingredient. Adv Food Nutr Res. 2003;47:113-73. doi: 10.1016/s1043-4526(03)47003-4. PMID: 14639783.
107.Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009 Jul 30;361(5):496-509. doi: 10.1056/NEJMra0804595. PMID: 19641206.
108.Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011 Feb;11(2):98-107. doi: 10.1038/nri2925. Epub 2011 Jan 14. PMID: 21233852.
109.Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1-7;365(9453):82-93. doi: 10.1016/S0140-6736(04)17670-8. PMID: 15639683.
110.Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Open Med. 2010;4(1):e60-8. Epub 2010 Mar 24. PMID: 21686296; PMCID: PMC3116666.
111.Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020 Jan;20(1):40-54. doi: 10.1038/s41577-019-0198-4. Epub 2019 Aug 6. PMID: 31388093.
112.Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012 Nov 10;31(25):2973-84. doi: 10.1002/sim.5403. Epub 2012 Jun 18. PMID: 22711298; PMCID: PMC3551627.
113. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30. Erratum in: PLoS Med. 2022 Aug 25;19(8):e1004085. doi: 10.1371/journal.pmed.1004085. PMID: 16060722; PMCID: PMC1182327.
114.Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12. PMID: 30310233.
115.Goel V, Lovlin R, Barton R, Lyon MR, Bauer R, Lee TD, Basu TK. Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2004 Feb;29(1):75-83. doi: 10.1111/j.1365-2710.2003.00542.x. PMID: 14748902.
116.Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008 Jul 24;454(7203):428-35. doi: 10.1038/nature07201. PMID: 18650913.
117.Calder PC, Ahluwalia N, Albers R, Bosco N, Bourdet-Sicard R, Haller D, Holgate ST, Jönsson LS, Latulippe ME, Marcos A, Moreines J, M'Rini C, Müller M, Pawelec G, van Neerven RJ, Watzl B, Zhao J. A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br J Nutr. 2013 Jan;109 Suppl 1:S1-34. doi: 10.1017/S0007114512005119. PMID: 23343744.
118.Ioannidis JP. Why most published research findings are false. PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30. Erratum in: PLoS Med. 2022 Aug 25;19(8):e1004085. doi: 10.1371/journal.pmed.1004085. PMID: 16060722; PMCID: PMC1182327.
119.Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015 Sep 23;351:h4633. doi: 10.1136/bmj.h4633. PMID: 26400751; PMCID: PMC4580726.
120.Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov. 2019 Jan;18(1):1-2. doi: 10.1038/nrd.2018.92. Epub 2018 Jun 8. PMID: 29880920.
121.Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008 Apr 3;358(14):1427-9. doi: 10.1056/NEJMp0802107. PMID: 18385495.
122.Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216. PMID: 27959688.
123.Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999 Aug 25;282(8):790-5. doi: 10.1001/jama.282.8.790. PMID: 10463719.
124.Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005 Jun 27;165(12):1363-9. doi: 10.1001/archinte.165.12.1363. PMID: 15983284.
125.Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013 May;14(5):365-76. doi: 10.1038/nrn3475. Epub 2013 Apr 10. Erratum in: Nat Rev Neurosci. 2013 Jun;14(6):451. PMID: 23571845.
126.Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989 Apr;8(4):431-40. doi: 10.1002/sim.4780080407. PMID: 2727467.
127.Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003 Mar;2(3):192-204. doi: 10.1038/nrd1032. PMID: 12612645.
128.Kaddurah-Daouk R, Weinshilboum RM; Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014 Feb;95(2):154-67. doi: 10.1038/clpt.2013.217. Epub 2013 Nov 5. PMID: 24193171.
129.Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001 Sep;8(5):401-9. doi: 10.1078/0944-7113-00060. PMID: 11695885.
130.Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002 Jun 6;45(12):2615-23. doi: 10.1021/jm020017n. PMID: 12036371.
131.Testa B, Krämer SD. The biochemistry of drug metabolism--an introduction: part 3. Reactions of hydrolysis and their enzymes. Chem Biodivers. 2007 Sep;4(9):2031-122. doi: 10.1002/cbdv.200790169. PMID: 17886859.
132.Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1-7;365(9453):82-93. doi: 10.1016/S0140-6736(04)17670-8. PMID: 15639683.
133.Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004 Oct;38(10):1702-6. doi: 10.1345/aph.1D374. Epub 2004 Aug 24. PMID: 15328391.
134.Ioannidis JP. Why most published research findings are false. PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30. Erratum in: PLoS Med. 2022 Aug 25;19(8):e1004085. doi: 10.1371/journal.pmed.1004085. PMID: 16060722; PMCID: PMC1182327.
135.Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004 May 26;291(20):2457-65. doi: 10.1001/jama.291.20.2457. PMID: 15161896.
136.Butterweck V, Nahrstedt A. What is the best strategy for preclinical testing of botanicals? A critical perspective. Planta Med. 2012 May;78(8):747-54. doi: 10.1055/s-0031-1298434. Epub 2012 Apr 12. PMID: 22499562.
137.Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007 Mar;1770(3):489-94. doi: 10.1016/j.bbagen.2006.09.019. Epub 2006 Oct 4. PMID: 17113714.
138.International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36. doi: 10.1038/nrd3028. PMID: 20190787; PMCID: PMC3326076.
139.Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012 Nov 10;31(25):2973-84. doi: 10.1002/sim.5403. Epub 2012 Jun 18. PMID: 22711298; PMCID: PMC3551627.
140.Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989 Apr;8(4):431-40. doi: 10.1002/sim.4780080407. PMID: 2727467.
141.Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999 Aug 25;282(8):790-5. doi: 10.1001/jama.282.8.790. PMID: 10463719.
142.DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016 May; 47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12. PMID: 26928437.
143.Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332. PMID: 20332509; PMCID: PMC2844940.
144.Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993 Apr 15;118(8):622-9. doi: 10.7326/0003-4819-118-8-199304150-00009. PMID: 8452328.
145.Bailey SA, Zidell RH, Perry RW. Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint? Toxicol Pathol. 2004 Jul-Aug;32(4):448-66. doi: 10.1080/01926230490465874. PMID: 15204968.
146.Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016 Feb 4;14:10. doi: 10.1186/s12916-016-0553-2. Erratum in: BMC Med. 2019 Mar 2;17(1):56. doi: 10.1186/s12916-019-1294-9. PMID: 26843061; PMCID: PMC4740994.
147.Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):629-40. doi: 10.1517/17425255.1.4.629. PMID: 16863429.
148.Wagner H. Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia. 2011 Jan;82(1):34-7. doi: 10.1016/j.fitote.2010.11.016. Epub 2010 Nov 12. PMID: 21075177.
149.Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003 Mar;9(3):269-77. doi: 10.1038/nm0303-269. PMID: 12612576.
150.Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015 May;15(5):283-94. doi: 10.1038/nri3823. Epub 2015 Apr 17. PMID: 25882245.
151.Ramuth M, Sonoo J, Mokshanand F, Herring B, Sofonias T, McCauley J, Dinasing A, Treurnicht FK. Molecular Evolution of Influenza A Viruses From Mauritius, 2017-2019. Influenza Other Respir Viruses. 2025 May;19(5):e70108. doi: 10.1111/irv.70108. PMID: 40360235; PMCID: PMC12074737.
152.File TM Jr. Case studies of lower respiratory tract infections: community-acquired pneumonia. Am J Med. 2010 Apr;123(4 Suppl):S4-15. doi: 10.1016/j.amjmed.2010.02.002. PMID: 20350635.
153.Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011 Aug 15;157C(3):175-82. doi: 10.1002/ajmg.c.30313. Epub 2011 Jul 15. PMID: 21766440.
154.Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1-7;365(9453):82-93. doi: 10.1016/S0140-6736(04)17670-8. PMID: 15639683.
155.Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 2008 Jan;21(1):70-83. doi: 10.1021/tx700079z. Epub 2007 Dec 6. PMID: 18052394.
156.Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-53. doi: 10.2165/00003088-200443100-00001. PMID: 15244495.
157.Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007 Jan 17;297(3):308-11. doi: 10.1001/jama.297.3.308. PMID: 17227983.
158.Garattini S, Bertele V. Adjusting Europe's drug regulation to public health needs. Lancet. 2001 Jul 7;358(9275):64-7. doi: 10.1016/s0140-6736(00)05258-2. PMID: 11454401.
159.Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006 May 8;166(9):1021-6. doi: 10.1001/archinte.166.9.1021. PMID: 16682577.
160.Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005 Jul 13;294(2):218-28. doi: 10.1001/jama.294.2.218. PMID: 16014596.
161.Frieden TR. Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. N Engl J Med. 2017 Aug 3;377(5):465-475. doi: 10.1056/NEJMra1614394. PMID: 28767357.
162.Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell. 2010 Mar 19;140(6):771-6. doi: 10.1016/j.cell.2010.03.006. PMID: 20303867.
163.Straub RH. The brain and immune system prompt energy shortage in chronic inflammation and ageing. Nat Rev Rheumatol. 2017 Dec;13(12):743-751. doi: 10.1038/nrrheum.2017.172. Epub 2017 Oct 12. PMID: 29021568.
164.Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009 Oct;9(10):679-91. doi: 10.1038/nri2622. Epub 2009 Sep 18. PMID: 19763149; PMCID: PMC2947825.
165.Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T. Pathogenesis of Atopic Dermatitis: Current Paradigm. Iran J Immunol. 2019 Jun;16(2):97-107. doi: 10.22034/IJI.2019.80253. PMID: 31182684.
166.Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 14;444(7121):860-7. doi: 10.1038/nature05485. PMID: 17167474.
167.Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997 Dec;49(4):403-49. PMID: 9443165.
168.Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470. PMID: 15286737.
169.Langer RS, Peppas NA. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials. 1981 Oct;2(4):201-14. doi: 10.1016/0142-9612(81)90059-4. PMID: 7034798.
170.Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003 Jul 31;90(3):261-80. doi: 10.1016/s0168-3659(03)00194-9. PMID: 12880694.
171.Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chem Rev. 2016 Feb 24;116(4):2602-63. doi: 10.1021/acs.chemrev.5b00346. Epub 2016 Feb 8. PMID: 26854975; PMCID: PMC5509216.
172.Smith DA, van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr Opin Chem Biol. 1999 Aug;3(4):373-8. doi: 10.1016/s1367-5931(99)80056-8. PMID: 10419843.
173.Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013 Oct 11;11:222. doi: 10.1186/1741-7015-11-222. Retraction in: BMC Med. 2024 Jul 4;22(1):279. doi: 10.1186/s12916-024-03504-x. PMID: 24120035; PMCID: PMC3851815.
174.Raclariu AC, Heinrich M, Ichim MC, de Boer H. Benefits and Limitations of DNA Barcoding and Metabarcoding in Herbal Product Authentication. Phytochem Anal. 2018 Mar;29(2):123-128. doi: 10.1002/pca.2732. Epub 2017 Sep 14. PMID: 28906059; PMCID: PMC5836936.
175.Techen N, Parveen I, Pan Z, Khan IA. DNA barcoding of medicinal plant material for identification. Curr Opin Biotechnol. 2014 Feb;25:103-10. doi: 10.1016/j.copbio.2013.09.010. Epub 2013 Nov 16. PMID: 24484887.
176.Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999 Nov;27(11):1350-9. PMID: 10534321.
177.Testa B, Krämer SD. The biochemistry of drug metabolism--an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers. 2007 Mar;4(3):257-405. doi: 10.1002/cbdv.200790032. PMID: 17372942.
178.Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005 May 26;352(21):2211-21. doi: 10.1056/NEJMra032424. PMID: 15917386.
179.Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002 Mar;71(3):115-21. doi: 10.1067/mcp.2002.121829. PMID: 11907485.
180.Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008 Jun;23(6):854-9. doi: 10.1007/s11606-008-0632-y. Epub 2008 Apr 16. PMID: 18415652; PMCID: PMC2517879.
181.Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200-5. doi: 10.1001/jama.279.15.1200. PMID: 9555760.
182.Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001 Mar;109 Suppl 1(Suppl 1):69-75. doi: 10.1289/ehp.01109s169. PMID: 11250806; PMCID: PMC1240543.
183.Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997 Dec;49(4):403-49. PMID: 9443165.
184.Thomford NE, Dzobo K, Chimusa E, Andrae-Marobela K, Chirikure S, Wonkam A, Dandara C. Personalized Herbal Medicine? A Roadmap for Convergence of Herbal and Precision Medicine Biomarker Innovations. OMICS. 2018 Jun;22(6):375-391. doi: 10.1089/omi.2018.0074. PMID: 29927715.
185.Cinti C, Trivella MG, Joulie M, Ayoub H, Frenzel M; International Consortium for Personalised Medicine and Working Group ‘Personalised Medicine in Healthcare’ (WG2). The Roadmap toward Personalized Medicine: Challenges and Opportunities. J Pers Med. 2024 May 21;14(6):546. doi: 10.3390/jpm14060546. PMID: 38929767; PMCID: PMC11204408.
186.Zaid N, Benchikhi L, Himmi B, Ghazal H. Bioinformatics applications in pharmacogenomics: towards personalized medicine. Gene. 2026 Feb 10;979:149935. doi: 10.1016/j.gene.2025.149935. Epub 2025 Dec 4. PMID: 41352693.
187.Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol. 2012 Apr 30;3:69. doi: 10.3389/fphar.2012.00069. PMID: 22557968; PMCID: PMC3339338.
188.Kessler CS, Perera PK, Puthiyedath R, Dhruva A. Editorial: The increasing relevance of traditional medicine systems for the primary health care sector and general practice: global research perspectives. Front Med (Lausanne). 2025 Jan 7;11:1533361. doi: 10.3389/fmed.2024.1533361. PMID: 39850098; PMCID: PMC11755042.
189.Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011 Jun;63(2):437-59. doi: 10.1124/pr.110.003533. Epub 2011 Mar 24. PMID: 21436344.
190.Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016 Apr;14(5):273-87. doi: 10.1038/nrmicro.2016.17. Epub 2016 Mar 14. PMID: 26972811; PMCID: PMC5243131.
191.Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015 Oct 15;526(7573):343-50. doi: 10.1038/nature15817. PMID: 26469045; PMCID: PMC4711261.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.
